MedAdvisor has been admitted once again to the Australian Securities Exchange following the reverse takeover of Exalt Resources Ltd by MedAdvisor International Pty Ltd.
“We are delighted to be listed on the ASX and look forward to delivering a number of exciting initiatives in 2016 to Australian pharmacies.” MedAdvisor CEO Robert Read said.
“The first day of trading has been strong [December 1, 2015], with the share price up 60 per cent in the first hour of trade. This is a pleasing outcome for all shareholders, but particularly those pharmacists who took advantage of the priority share offer. As a company, we’ve achieved a lot in a short space of time, including establishing important marketing partnerships with pharmaceutical companies GSK, AstraZeneca, UCB, Allergan, Apotex and, most recently, Amgen.”